Articles with the topic: featured

How many is too many? Exploring the toxic CAG threshold in the Huntington’s disease brain

How many is too many? Exploring the toxic CAG threshold in the Huntington’s disease brain

New work from researchers in London uses mice to narrow in on the number of CAG repeats needed to cause symptoms of Huntington’s disease. Their work points to fewer than 185 CAGs as a threshold.

Dr Sarah HernandezApril 21, 2024

Cry your eyes out: detecting huntingtin in tears

Cry your eyes out: detecting huntingtin in tears

Is someone cutting onions? Expanded huntingtin can now be detected in tears to help scientists track disease progression.

Dr Leora FoxApril 10, 2024

The director’s cut: how CAG repeats change the editing of genetic messages

The director’s cut: how CAG repeats change the editing of genetic messages

Scientists in Massachusetts have recently advanced our understanding of how repetitive sequences in DNA can disrupt the creation and editing of genetic messenger molecules in cells, and how this could lead to the production of harmful proteins.

Dr Rachel HardingMarch 26, 2024

Understanding expansions at the single cell level

Understanding expansions at the single cell level

Scientists have looked at CAG expansions in brains from people with HD to see which cells are affected

Dr Rachel HardingMarch 12, 2024

Huntington's Disease Therapeutics Conference 2024 - Day 3

Huntington's Disease Therapeutics Conference 2024 - Day 3

Dr Rachel Harding, Dr Leora Fox, and Dr Sarah HernandezMarch 07, 2024

Huntington's Disease Therapeutics Conference 2024 - Day 2

Huntington's Disease Therapeutics Conference 2024 - Day 2

Dr Rachel Harding, Dr Sarah Hernandez, and Dr Leora FoxMarch 06, 2024

Huntington's Disease Therapeutics Conference 2024 - Day 1

Huntington's Disease Therapeutics Conference 2024 - Day 1

Check out research updates from Day 1 of the 2024 HD Therapeutics Conference #HDTC2024

Dr Rachel Harding, Dr Sarah Hernandez, and Dr Leora FoxMarch 05, 2024

CRISPR-based drugs: one giant leap for mankind

CRISPR-based drugs: one giant leap for mankind

Casgevy is the first CRISPR-based drug to make its way through the approval process, all but curing Sickle Cell Disease and it’s paving the way for similar drugs targeting other diseases. Is Huntington’s disease next?

Dr Rachel HardingFebruary 14, 2024

Steady progress from uniQure - promising data to end the year

Steady progress from uniQure - promising data to end the year

uniQure ushered in the end of the year by releasing some promising data from their huntingtin-lowering gene therapy trials

Dr Rachel HardingDecember 20, 2023